Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GNNSF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GNNSF and 80,000+ other tickers.
See exactly how GNNSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GNNSF and 80,000+ other tickers.
Genscript Biotech Corporation, an investment holding firm, operates on a global scale as a leading provider of life science research products and services, serving North America, Europe, China, Japan, other Asia Pacific regions, and beyond. The company is structured into four distinct business units. Its Life Science Services and Products division delivers essential research support, encompassing gene synthesis, molecular cloning, oligonucleotide and peptide synthesis, protein engineering, antibody development, and the creation of molecular diagnostic tools and genome editing materials. These…
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ProBio: US$388.7 million, +309.1% year-on-year Bestzyme: US$58.0 million, +7.9% year-on-year PISCATAWAY, N.J., March 16, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology innovation, today announced financial results for full year 2025.
Genscript Biotech Corporation (OTCPK:GNNSF) Q2 2025 Earnings Conference Call August 17, 2025 7:00 PM ET Company Participants Aixi Bai - General Manager of Bestzyme Allen Guo - CEO of ProBio Josie Zhou - Interim CFO Ray Chen - President of GenScript Life Science Group Weihui Shao - CEO & COO Conference Call Participants Daisy Cheng - Morgan Stanley, Research Division Wai Chak Yuen - Daiwa Securities Co. Ltd., Research Division Wanhua Wu - China International Capital Corporation Limited, Research Division Yang Huang - JPMorgan Chase & Co, Research Division Good day and thank you for standing by.
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J. , Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation.
PISCATAWAY, N.J. , July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating has been upgraded to AA from A by MSCI in recognition of the company's excellence in the areas of product safety & quality and human capital development, as well as continuous improvement in environment and governance practices.